Insmed(INSM)
BRIDGEWATER, NJ
Biotechnology6 H-1B visas (FY2023)Focus: Inhalable Liposomal Therapeutics
Insmed is a life sciences company focused on Inhalable Liposomal Therapeutics.
NeurologyRare DiseasesCardiovascularRespiratoryOphthalmology
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
83
Products & Portfolio (2)
1 discontinued product not shown
ARIKAYCE KIT
amikacin
Peak
INHALATION · SUSPENSION, LIPOSOMAL
12.1 Mechanism of Action ARIKAYCE is an antibacterial drug [see ]. 12.2 Pharmacodynamics ARIKAYCE exposure-response relationships and the time course of pharmacodynamic response are unknown. 12.3 Pharmacokinetics Sputum Concentrations Following once daily inhalation of 590 mg ARIKAYCE in Mycobacterium avium complex (MAC) patients, sputum concentrations at 1 to 4 hours post-inhalation were 1720, 884, and 1300 mcg/g at 1, 3, and 6 months, respectively. High variability in amikacin concentrations were observed (CV% >100%). After 48 to 72 hours post-inhalation, amikacin sputum concentrations decreased to approximately 5% of those at 1 to 4 hours post-inhalation. Serum Concentrations Following 3 months of once daily inhalation of 590 mg ARIKAYCE in MAC patients, the mean serum AUC 0-24 was 23.5 mcg*hr/mL (range: 8.0 to 46.5 mcg*hr/mL; n=12) and the mean serum C max was 2.8 mcg/mL (range: 1.0 to 4.4 µg/mL; n=12). The maximum C max and AUC 0-24 were below the mean C max of approximately 76 mcg/mL and AUC 0-24 of 154 mcg*hr/mL observed for intravenous administration of amikacin sulfate for injection at the approved dosage of 15 mg/kg once daily in healthy adults. Absorption The bioavailability of ARIKAYCE is expected to vary primarily from individual differences in nebulizer efficiency and airway pathology. Distribution The protein binding of amikacin in serum is ≤ 10%. Elimination Following inhalation of ARIKAYCE in MAC patients, the apparent serum half-life of amikacin ranged from approximately 5.9 to 19.5 hrs. Metabolism Amikacin does not undergo appreciable metabolism. Excretion Systemically absorbed amikacin following ARIKAYCE administration is eliminated principally via glomerular filtration. On average, 7.42% (ranging from 0.72 to 22.60%; n=14) of the total ARIKAYCE dose was excreted in urine as unchanged drug compared to 94% following intravenous administration of amikacin sulfate for injection. Unabsorbed amikacin, following ARIKAYCE inhalation, is probably eliminated primarily by cellular turnover and expectoration. Drug Interaction Studies No clinical drug interaction studies have been conducted with ARIKAYCE [see ]. 12.4 Microbiology Mechanism of Action Amikacin is a polycationic, semisynthetic, bactericidal aminoglycoside. Amikacin enters the bacterial cell by binding to negatively charged components of the bacterial cell wall disrupting the overall architecture of the cell wall. The primary mechanism of action is the disruption and inhibition of protein synthesis in the target bacteria by binding to the 30S ribosomal subunit. Resistance The mechanism of resistance to amikacin in mycobacteria has been linked to mutations in the rrs gene of the 16S rRNA. In clinical trials, MAC isolates developing an amikacin MIC of > 64 mcg/mL after baseline were observed in a higher proportion of subjects treated with ARIKAYCE [see ] . Interaction with Other Antimicrobials There has been no in vitro signal for antagonism between amikacin and other antimicro
no alternative treatment optionsfor the treatment of Mycobacterium avium complex (MAC) lung disease
2018
0
BRINSUPRI
brensocatib
Launch
ORAL · TABLET
competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 activates pro-inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone marrow. Activated NSPs are implicated in the pathogenesis of neutrophil-mediated NCFB inflammation. In cell-based assays, DPP1 inhibition by brensocatib reduces the activity of NSPs including neutrophil elastase, cathepsin G, and proteinase 3.
non-cystic fibrosis bronchiectasis in adultolder
2025
0
Pipeline & Clinical Trials
Brensocatib
Non-Cystic Fibrosis BronchiectasisClinical Trials (1)
NCT05344508An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis
N/ATreprostinil Palmitil
Pulmonary Arterial HypertensionClinical Trials (1)
NCT06939647An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
N/ADevelopment of a Canadian Bronchiectasis and NTM Database
BronchiectasisClinical Trials (1)
NCT06144996Development of a Canadian Bronchiectasis and NTM Database
N/ABrensocatib
Healthy VolunteersClinical Trials (1)
NCT05965570A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
Phase 1Brensocatib
Hepatic ImpairmentClinical Trials (1)
NCT05517525A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
Phase 1INS1201
Duchenne Muscular DystrophyClinical Trials (1)
NCT06817382A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
Phase 1[14C]-brensocatib
Healthy VolunteersClinical Trials (1)
NCT05652257A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants
Phase 1SLIT™ Amikacin
Cystic FibrosisClinical Trials (1)
NCT06238856Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
Phase 1Liposomal Amikacin for Inhalation
Healthy VolunteersClinical Trials (1)
NCT05999942A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants
Phase 1INS1007
Healthy VolunteersClinical Trials (1)
NCT05927597A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants
Phase 1TPIP F2
Healthy VolunteersClinical Trials (1)
NCT07102316A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants
Phase 1Phase 1
Clinical Trials (1)
NCT07290062A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Phase 1Brensocatib Oral Solution
Healthy ParticipantsClinical Trials (1)
NCT06344728A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
Phase 1Treprostinil Palmitil Inhalation Powder
Healthy VolunteersClinical Trials (1)
NCT06091579A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
Phase 1Brensocatib
Healthy VolunteerClinical Trials (1)
NCT05355935A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants
Phase 1Brensocatib
Renal ImpairmentClinical Trials (1)
NCT05673603A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment
Phase 1Brensocatib
Healthy VolunteersClinical Trials (1)
NCT05826574A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
Phase 1C16TR
Healthy VolunteersClinical Trials (1)
NCT06193031A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
Phase 1Brensocatib
Healthy VolunteersClinical Trials (1)
NCT06178783A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
Phase 1ARIKACE™
Cystic FibrosisClinical Trials (1)
NCT00777296Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
Phase 1/2Cisplatin liposomal
Osteosarcoma MetastaticClinical Trials (1)
NCT00102531Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Phase 1/2Arikayce™ 560 mg
Cystic FibrosisClinical Trials (1)
NCT00558844Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Phase 1/2Nordihydroguaiaretic Acid
Prostate CancerClinical Trials (1)
NCT00678015Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer
Phase 2rhIGF-1/rhIGFBP-3
Noonan SyndromeClinical Trials (1)
NCT00351221Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
Phase 2Brensocatib 10 mg
Non-Cystic Fibrosis BronchiectasisClinical Trials (1)
NCT03218917Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
Phase 2Brensocatib
Cystic FibrosisClinical Trials (1)
NCT05090904A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Phase 2LAI plus multi-drug regimen
Mycobacterium Infections, NontuberculousClinical Trials (1)
NCT03038178Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
Phase 2Treprostinil Palmitil
Pulmonary Arterial HypertensionClinical Trials (1)
NCT05147805A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Phase 2Liposomal amikacin for inhalation
Mycobacterium Infections, NontuberculousClinical Trials (1)
NCT01315236Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria
Phase 2Brensocatib
Chronic Rhinosinusitis Without Nasal PolypsClinical Trials (1)
NCT06013241A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Phase 2Brensocatib
Hidradenitis SuppurativaClinical Trials (1)
NCT06685835A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Phase 2Arikayce™
Cystic FibrosisClinical Trials (1)
NCT03905642Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
Phase 2Treprostinil Palmitil
Pulmonary Arterial HypertensionClinical Trials (1)
NCT04791514A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
Phase 2280 mg Arikayce™
BronchiectasisClinical Trials (1)
NCT00775138Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
Phase 2Treprostinil Palmitil
Pulmonary HypertensionClinical Trials (1)
NCT05176951A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Phase 2rhIGF-I/rhIGFBP-3
Myotonic Dystrophy Type 1Clinical Trials (1)
NCT00577577Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Phase 2Treprostinil Palmitil Inhalation Powder
Pulmonary HypertensionClinical Trials (1)
NCT05649722An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase 2/3rhIGF-I/rhIGFBP-3
Growth Hormone Insensitivity Syndrome (GHIS)Clinical Trials (1)
NCT00368173IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome
Phase 2/3Treprostinil Palmitil
Pulmonary Arterial HypertensionClinical Trials (1)
NCT05649748An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Phase 2/3LAI 590 mg
NTM Lung Infection Due to MACClinical Trials (1)
NCT02628600Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212
Phase 3Phase 3
Clinical Trials (1)
NCT04677543Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Phase 3Liposomal amikacin for inhalation
Pseudomonas Aeruginosa InfectionClinical Trials (1)
NCT01315678Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
Phase 3Phase 3
Clinical Trials (1)
NCT02344004Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
Phase 3Treprostinil Palmitil Inhalation Powder
Pulmonary HypertensionClinical Trials (1)
NCT07234032An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase 3Phase 3
Clinical Trials (1)
NCT04677569Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Phase 3Brensocatib
Covid19Clinical Trials (1)
NCT04817332STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19
Phase 3Liposomal amikacin for inhalation
Cystic FibrosisClinical Trials (1)
NCT01315691Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Phase 3Treprostinil Palmitil Inhalation Powder
Pulmonary HypertensionClinical Trials (1)
NCT07179380Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Phase 3Brensocatib 10 mg
Non-Cystic Fibrosis BronchiectasisClinical Trials (1)
NCT04594369A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
Phase 3Liposomal amikacin for inhalation
Cystic FibrosisClinical Trials (1)
NCT01316276Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
Phase 3Open Jobs (83)
Senior Programmer
NJ Corporate Headquarters
23h ago
$113K - $144K/yr
Senior Scientist
Research Development Lab - New Hampshire
23h ago
$127K - $166K/yr
Specialist, Drug Safety & Pharmacovigilance Compliance
NJ Corporate Headquarters
23h ago
$42 - $53/hr
Senior Systems Administrator (SysAdmin)
Research Development Lab - Cambridge
23h ago
Senior Scientist, Discovery Pharmacology
Research Development Lab - New Jersey
23h ago
$127K - $166K/yr
Senior Research Associate, Discovery Pharmacology (R)
Research Development Lab - New Jersey
23h ago
$80K - $102K/yr
Director, In Vivo Research
NJ Corporate Headquarters
Yesterday
$185K - $253K/yr
Executive Director, Clinical Program Lead
NJ Corporate Headquarters
Yesterday
$306K - $417K/yr
Senior Scientist
Research Development Lab - New Hampshire
Yesterday
$127K - $166K/yr
Sr Director, Programming Infrastructure & Analytics Enablement
NJ Corporate Headquarters
Yesterday
$222K - $303K/yr
Systems Engineer II
NJ Corporate Headquarters
Yesterday
$113K - $144K/yr
IT Systems Engineer II (GxP)
NJ Corporate Headquarters
Yesterday
$113K - $144K/yr
Senior Analyst, Quality Assurance
NJ Corporate Headquarters
Yesterday
$100K - $127K/yr
Senior Director, Small molecule -Analytical development and QC
NJ Corporate Headquarters
Yesterday
$214K - $292K/yr
Senior Engineer, Supplier Quality
NJ Corporate Headquarters
Yesterday
$100K - $127K/yr
Senior Scientist Formulation and Process Development
NJ Corporate Headquarters
Yesterday
$124K - $161K/yr
QMS Specialist, Quality Assurance
Research Development Lab - San Diego
Yesterday
$81K - $103K/yr
Director, US Patient Advocacy & Professional Engagement
NJ Corporate Headquarters
2d ago
$177K - $242K/yr
Director, Patient & Professional Advocacy, Market Development
NJ Corporate Headquarters
2d ago
$177K - $242K/yr
Therapeutic Specialist, Peoria, IL
Peoria, IL
4d ago
$155K - $202K/yr
Director, Insights, Diagnosis Acceleration
NJ Corporate Headquarters
4d ago
$177K - $242K/yr
Therapeutic Specialist, Belleville IL
Belleville, IL
4d ago
$155K - $202K/yr
Vice President, Product Development - CMC, Small Molecules
NJ Corporate Headquarters
5d ago
$290K - $396K/yr
Associate Director, Regulatory Affairs CMC, EMEA
UK
5d ago
Senior Associate, Supplier Relationship Management
NJ Corporate Headquarters
5d ago
$81K - $103K/yr
Interview Prep Quick Facts
Portfolio: 3 approved products, 50 clinical trials
Top TAs: Rare Diseases, Cardiovascular, Respiratory
H-1B (2023): 6 approvals
SEC Filings: 2 available
Open Roles: 83 active jobs
Portfolio Health
Launch1 (33%)
Peak1 (33%)
LOE Approaching1 (33%)
3 total products
Therapeutic Area Focus
Rare Diseases
1 marketed11 pipeline
Cardiovascular
8 pipeline
Respiratory
1 marketed3 pipeline
Infectious Diseases
1 marketed
Gastroenterology
1 pipeline
Nephrology
1 pipeline
Neurology
1 pipeline
Oncology
1 pipeline
Marketed
Pipeline
Financials (FY2025)
Revenue
$305M24%
R&D Spend
$571M(187%)44%
Net Income
-$750MCash
$555MHiring Trend
Actively Hiring
83
Open Roles
+54
Added
-11
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
6
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub